P van de Kerkhof
Overview
Explore the profile of P van de Kerkhof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burden A, Okubo Y, Zheng M, Thaci D, van de Kerkhof P, Hu N, et al.
Exp Dermatol
. 2023 May;
32(8):1279-1283.
PMID: 37140190
Effisayil 1 was a multicentre, randomized, double-blind, placebo-controlled study of the anti-interleukin (IL)-36 receptor monoclonal antibody, spesolimab, in patients presenting with a generalized pustular psoriasis (GPP) flare. Previously published data...
2.
Golbari N, van der Walt J, Blauvelt A, Ryan C, van de Kerkhof P, Kimball A
J Eur Acad Dermatol Venereol
. 2020 Sep;
35(2):417-421.
PMID: 32978847
Background: Psoriasis severity is usually evaluated using quantitative and qualitative measures, including per cent body surface area (BSA) involvement, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life...
3.
Blauvelt A, Paul C, van de Kerkhof P, Warren R, Gottlieb A, Langley R, et al.
Br J Dermatol
. 2020 Jun;
184(4):640-651.
PMID: 32531798
Background: Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic. Objectives: To report 3-year safety data from three phase III trials of CZP in adults with plaque psoriasis....
4.
Warren R, Barker J, van de Kerkhof P, Reich K, Mrowietz U
J Eur Acad Dermatol Venereol
. 2019 Apr;
33(10):e352-e353.
PMID: 31033034
No abstract available.
5.
Iversen L, Eidsmo L, Austad J, de Rie M, Osmancevic A, Skov L, et al.
J Eur Acad Dermatol Venereol
. 2018 Apr;
32(11):1930-1939.
PMID: 29633373
Background: To date, biological treatments have been assessed in subjects with a long-term history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid arthritis and other immune-mediated...
6.
Nast A, Spuls P, Van Der Kraaij G, Gisondi P, Paul C, Ormerod A, et al.
J Eur Acad Dermatol Venereol
. 2017 Sep;
31(12):1951-1963.
PMID: 28895202
No abstract available.
7.
Guenther L, Warren R, Cather J, Sofen H, Poulin Y, Lebwohl M, et al.
J Eur Acad Dermatol Venereol
. 2017 Jun;
31(11):1867-1875.
PMID: 28573743
Background: Psoriasis symptoms may decrease quality of life for patients. Skin-related personal relationship difficulties in psoriasis patients are common, under-reported and poorly understood. Objective: To assess the effect of ixekizumab...
8.
van de Kerkhof P, Guenther L, Gottlieb A, Sebastian M, Wu J, Foley P, et al.
J Eur Acad Dermatol Venereol
. 2016 Dec;
31(3):477-482.
PMID: 27910156
Background: Fingernail psoriasis is difficult to treat. Objective: The objective was to evaluate the effect of ixekizumab, a monoclonal antibody selectively targeting IL-17A, on fingernail psoriasis. Methods: This Phase 3,...
9.
Mrowietz U, Szepietowski J, Loewe R, van de Kerkhof P, Lamarca R, Ocker W, et al.
Br J Dermatol
. 2016 Aug;
176(3):615-623.
PMID: 27515097
Background: Fumaric acid esters (FAEs) are recommended in international guidelines for induction and long-term treatment of adults with moderate-to-severe chronic plaque psoriasis. The fixed combination Fumaderm is approved in Germany,...
10.
Nast A, Gisondi P, Ormerod A, Saiag P, Smith C, Spuls P, et al.
J Eur Acad Dermatol Venereol
. 2015 Oct;
29(12):2277-94.
PMID: 26481193
No abstract available.